INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...
GUILDFORD, SURREY / ACCESS Newswire / July 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research ...
DUBLIN and MUNICH - August 28, 2018 - Medtronic plc (NYSE:MDT) today announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life, reduced symptoms from ...
GUILDFORD, UK / ACCESSWIRE / September 28, 2022 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University of Birmingham has ...
Development of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay successfully completed for AstraZeneca Results of Eisai Phase 2 pilot study supports the ...
ANGLE plc STUDY USING PARSORTIX DEMONSTRATES IMPORTANCE OF BIOMARKER-INDEPENDENT CTC ISOLATION IN HEAD AND NECK CANCER EMT status of CTCs found to provide additional insight to tumour tissue biopsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback